Cargando…

Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study

HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in ru...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakeham, Katie, Johnston, W Thomas, Nalwoga, Angela, Webb, Emily L, Mayanja, Billy N, Miley, Wendell, Elliott, Alison M, Whitby, Denise, Newton, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529666/
https://www.ncbi.nlm.nih.gov/pubmed/25395177
http://dx.doi.org/10.1002/ijc.29329
_version_ 1782384813816152064
author Wakeham, Katie
Johnston, W Thomas
Nalwoga, Angela
Webb, Emily L
Mayanja, Billy N
Miley, Wendell
Elliott, Alison M
Whitby, Denise
Newton, Robert
author_facet Wakeham, Katie
Johnston, W Thomas
Nalwoga, Angela
Webb, Emily L
Mayanja, Billy N
Miley, Wendell
Elliott, Alison M
Whitby, Denise
Newton, Robert
author_sort Wakeham, Katie
collection PubMed
description HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently developed HIV-related KS (cases) and among 108 matched HIV/KSHV coinfected controls who did not develop KS. Throughout the 6 years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls (p < 0.0001), and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls, compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the pathogenesis of HIV-related KS in this setting.
format Online
Article
Text
id pubmed-4529666
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-45296662015-08-13 Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study Wakeham, Katie Johnston, W Thomas Nalwoga, Angela Webb, Emily L Mayanja, Billy N Miley, Wendell Elliott, Alison M Whitby, Denise Newton, Robert Int J Cancer Infectious Causes of Cancer HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently developed HIV-related KS (cases) and among 108 matched HIV/KSHV coinfected controls who did not develop KS. Throughout the 6 years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls (p < 0.0001), and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls, compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the pathogenesis of HIV-related KS in this setting. Blackwell Publishing Ltd 2015-06-15 2014-11-14 /pmc/articles/PMC4529666/ /pubmed/25395177 http://dx.doi.org/10.1002/ijc.29329 Text en © 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Infectious Causes of Cancer
Wakeham, Katie
Johnston, W Thomas
Nalwoga, Angela
Webb, Emily L
Mayanja, Billy N
Miley, Wendell
Elliott, Alison M
Whitby, Denise
Newton, Robert
Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title_full Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title_fullStr Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title_full_unstemmed Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title_short Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
title_sort trends in kaposi's sarcoma-associated herpesvirus antibodies prior to the development of hiv-associated kaposi's sarcoma: a nested case-control study
topic Infectious Causes of Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529666/
https://www.ncbi.nlm.nih.gov/pubmed/25395177
http://dx.doi.org/10.1002/ijc.29329
work_keys_str_mv AT wakehamkatie trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT johnstonwthomas trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT nalwogaangela trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT webbemilyl trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT mayanjabillyn trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT mileywendell trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT elliottalisonm trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT whitbydenise trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy
AT newtonrobert trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy